JP2008500277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500277A5 JP2008500277A5 JP2006552536A JP2006552536A JP2008500277A5 JP 2008500277 A5 JP2008500277 A5 JP 2008500277A5 JP 2006552536 A JP2006552536 A JP 2006552536A JP 2006552536 A JP2006552536 A JP 2006552536A JP 2008500277 A5 JP2008500277 A5 JP 2008500277A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- days
- human immunoglobulin
- administration
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims 10
- 102000018358 immunoglobulin Human genes 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/778,915 US20050180979A1 (en) | 2004-02-13 | 2004-02-13 | Anti-EpCAM immunoglobulins |
| US10/778,915 | 2004-02-13 | ||
| PCT/EP2005/001307 WO2005080428A2 (en) | 2004-02-13 | 2005-02-09 | Anti-epcam immunoglobulins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008500277A JP2008500277A (ja) | 2008-01-10 |
| JP2008500277A5 true JP2008500277A5 (enExample) | 2008-04-03 |
| JP5220315B2 JP5220315B2 (ja) | 2013-06-26 |
Family
ID=34838270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552536A Expired - Fee Related JP5220315B2 (ja) | 2004-02-13 | 2005-02-09 | 抗ＥｐＣＡＭ免疫グロブリン |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20050180979A1 (enExample) |
| EP (2) | EP2107071A3 (enExample) |
| JP (1) | JP5220315B2 (enExample) |
| KR (1) | KR101236224B1 (enExample) |
| CN (1) | CN1976951B (enExample) |
| AT (1) | ATE437186T1 (enExample) |
| AU (1) | AU2005215874B2 (enExample) |
| BR (1) | BRPI0507660A (enExample) |
| CA (1) | CA2555694C (enExample) |
| DE (1) | DE602005015544D1 (enExample) |
| DK (1) | DK1713830T3 (enExample) |
| EA (1) | EA011951B1 (enExample) |
| ES (1) | ES2328159T3 (enExample) |
| IL (1) | IL177069A (enExample) |
| MX (1) | MXPA06008942A (enExample) |
| NO (1) | NO339364B1 (enExample) |
| NZ (1) | NZ549125A (enExample) |
| PL (1) | PL1713830T3 (enExample) |
| PT (1) | PT1713830E (enExample) |
| SI (1) | SI1713830T1 (enExample) |
| UA (1) | UA87128C2 (enExample) |
| WO (1) | WO2005080428A2 (enExample) |
| ZA (1) | ZA200606083B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5686493B2 (ja) | 2003-01-24 | 2015-03-18 | ユニバーシティ・オブ・ユタＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｕｔａｈ | テロメアの長さを決定することによって死亡の危険性を予測する方法 |
| EP2004695A2 (en) | 2005-07-08 | 2008-12-24 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
| US7976842B2 (en) * | 2006-02-09 | 2011-07-12 | Micromet Ag | Treatment of metastatic breast cancer |
| EP2041181B1 (en) * | 2006-06-08 | 2011-05-18 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Specific protease inhibitors and their use in cancer therapy |
| EP1865001A1 (en) * | 2006-06-08 | 2007-12-12 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Specific protease inhibitors and their use in cancer therapy |
| ES2367675T3 (es) * | 2007-04-04 | 2011-11-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Anticuerpo anti-epcam y usos del mismo. |
| JP5840950B2 (ja) | 2008-12-22 | 2016-01-06 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | 単色マルチプレックス定量ｐｃｒ |
| JP6048660B2 (ja) * | 2009-09-21 | 2016-12-21 | ランジュ ラルハン | 甲状腺癌を診断および処置するための方法および組成物 |
| CN104168916B (zh) * | 2012-03-02 | 2017-07-04 | 中央研究院 | 抗上皮细胞黏着分子(EpCAM)抗体及其使用方法 |
| CN103387988B (zh) * | 2012-09-24 | 2016-01-06 | 厦门大学 | 上皮细胞粘附分子的核酸适体EpCAM Ccut及其制备方法 |
| CN105283559A (zh) | 2013-05-22 | 2016-01-27 | 端粒诊断公司 | 短端粒丰度的量度 |
| CN103275226B (zh) * | 2013-06-09 | 2017-08-29 | 中国科学技术大学 | 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用 |
| AU2015204766B2 (en) * | 2014-01-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| AU2015372584A1 (en) | 2014-12-30 | 2017-06-29 | Telomere Diagnostics, Inc. | Multiplex quantitative PCR |
| EP3903818A1 (en) * | 2015-11-19 | 2021-11-03 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| AU2017301826A1 (en) | 2016-07-26 | 2019-03-14 | Tessa Therapeutics Ltd. | Chimeric antigen receptor |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5853697A (en) * | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
| TR199902553T2 (xx) * | 1997-04-14 | 2000-03-21 | Micromet Gesellschaft F�R Biomedizinische Forschung Mbh | �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�. |
| US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| KR100900166B1 (ko) * | 2001-05-03 | 2009-06-02 | 메르크 파텐트 게엠베하 | 재조합 종양 특이적 항체 및 이들의 용도 |
| US20030175268A1 (en) * | 2002-01-11 | 2003-09-18 | Saint-Remy Jean-Marie R. | Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome |
| EP1575491A4 (en) * | 2002-05-20 | 2006-09-27 | Abgenix Inc | TREATMENT OF RENAL CARCINOMA USING ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR |
-
2004
- 2004-02-13 US US10/778,915 patent/US20050180979A1/en not_active Abandoned
-
2005
- 2005-02-09 PT PT05707293T patent/PT1713830E/pt unknown
- 2005-02-09 DE DE602005015544T patent/DE602005015544D1/de not_active Expired - Lifetime
- 2005-02-09 EA EA200601386A patent/EA011951B1/ru not_active IP Right Cessation
- 2005-02-09 CA CA2555694A patent/CA2555694C/en not_active Expired - Fee Related
- 2005-02-09 AU AU2005215874A patent/AU2005215874B2/en not_active Ceased
- 2005-02-09 EP EP09165284A patent/EP2107071A3/en not_active Withdrawn
- 2005-02-09 CN CN2005800099764A patent/CN1976951B/zh not_active Expired - Fee Related
- 2005-02-09 UA UAA200608985A patent/UA87128C2/ru unknown
- 2005-02-09 DK DK05707293T patent/DK1713830T3/da active
- 2005-02-09 EP EP05707293A patent/EP1713830B1/en not_active Expired - Lifetime
- 2005-02-09 ES ES05707293T patent/ES2328159T3/es not_active Expired - Lifetime
- 2005-02-09 KR KR1020067016339A patent/KR101236224B1/ko not_active Expired - Fee Related
- 2005-02-09 US US10/589,450 patent/US20070274982A1/en not_active Abandoned
- 2005-02-09 NZ NZ549125A patent/NZ549125A/en not_active IP Right Cessation
- 2005-02-09 BR BRPI0507660-9A patent/BRPI0507660A/pt not_active Application Discontinuation
- 2005-02-09 MX MXPA06008942A patent/MXPA06008942A/es active IP Right Grant
- 2005-02-09 SI SI200530759T patent/SI1713830T1/sl unknown
- 2005-02-09 JP JP2006552536A patent/JP5220315B2/ja not_active Expired - Fee Related
- 2005-02-09 WO PCT/EP2005/001307 patent/WO2005080428A2/en not_active Ceased
- 2005-02-09 AT AT05707293T patent/ATE437186T1/de active
- 2005-02-09 PL PL05707293T patent/PL1713830T3/pl unknown
-
2006
- 2006-07-21 ZA ZA200606083A patent/ZA200606083B/en unknown
- 2006-07-25 IL IL177069A patent/IL177069A/en not_active IP Right Cessation
- 2006-09-13 NO NO20064136A patent/NO339364B1/no not_active IP Right Cessation
-
2012
- 2012-06-01 US US13/486,749 patent/US20120294873A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2981830T3 (es) | Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres | |
| JP2007500236A5 (enExample) | ||
| JP2009506790A5 (enExample) | ||
| JP2020515578A5 (enExample) | ||
| JP2004501101A5 (enExample) | ||
| JP2013533858A5 (enExample) | ||
| RU2020115713A (ru) | Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения | |
| JP2017160208A5 (enExample) | ||
| RU2021130306A (ru) | Композиции il-12, нацеленные на edb | |
| JP2014515763A5 (enExample) | ||
| JP2012518686A5 (enExample) | ||
| JP2009505676A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| RU2013142004A (ru) | Конъюгаты "антитело-лекарственное средство" | |
| JP2011103891A5 (enExample) | ||
| JP2021513536A5 (enExample) | ||
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
| JP2015517523A5 (enExample) | ||
| JP2018512402A5 (enExample) | ||
| ES2328159T3 (es) | Inmunoglobulinas anti-epcam. | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| WO2021129616A1 (zh) | 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法 | |
| JP2008154589A5 (enExample) | ||
| RU2011130522A (ru) | Моноклональное антитело против hcv в качестве лекарственного средства для терапевтического лечения и профилактики инфекций hcv |